Microtubule active agents: Beyond the taxane frontier

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7167-7172

  Morris, Patrick G ^a   Fornier, Monica N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

21 AMINOEPOTHILONE B; 9,10 DIDEHYDROEPOTHILONE D; ABJ 879; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CREMOPHOR; CYCLOPHOSPHAMIDE; CYCLOSTREPTIN; DICTYOSTATIN; DISCODERMOLIDE; DOXORUBICIN; ELEUTHEROBIN; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; GEMCITABINE; HUMAN ALBUMIN; IMATINIB; IXABEPILONE; LAULIMALIDE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PELORUSIDE A; SAGOPILONE; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; TAXOID; TUBULIN MODULATOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BINDING SITE; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BREAST CANCER; CELL TRANSPORT; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; DIARRHEA; DRUG ACTIVITY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; ESOPHAGUS CANCER; FATIGUE; GLIOMA; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MELANOMA; METASTASIS; MICROTUBULE; MITOSIS; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR RESISTANCE; ANIMAL; DRUG EFFECT; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MICROTUBULES; NEOPLASMS; TAXOIDS; TUBULIN MODULATORS;

EID: 58149347705     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0169     Document Type: Review

References (63)

1. Gelfand VI, Bershadsky AD. Microtubule dynamics: mechanism, regulation, and function. Annu Rev Cell Biol 1991;7:93-116.
2. Rowinsky EK, Calvo E. Novel agents that target tubulin and related elements. Semin Oncol 2006;33:421-35.
3. Rai SS, Wolff J. Localization of the vinblastine-binding site on β-tubulin. J Biol Chem 1996;271:14707-11.
4. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23:7785-93.
5. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803.
6. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006;17:1263-8.
7. Stinchcombe TE, Socinski MA, Walko CM, et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 2007;60:759-66.
8. Seidman A, Danso M, Bach A, et al. Phase II study of weekly nanoparticle paclitaxel (ABI-007), carboplatin and trastuzumab as first-line therapy of HER2-positive metastatic breast cancer. J Clin Oncol 2006 ASCO Annu Meet Proc 2006;24:10650.
9. Dickler M, Traina T, Panageas K, et al. Adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanopar ticle albumin- bound paclitaxel (nab-p) in early stage breast cancer patients: cardiac safety. J Clin Oncol 2007 ASCO Annu Meet Proc 2007;25:567.
10. Khan M, Sharef S, Amato RJ. Phase II study of xyotax (PPX) for androgen independent prostate cancer (AIPC). J Clin Oncol 2006 ASCO Annu Meet Proc 2006;24:14624.
11. Nemunaitis JJ, Leighl N, Miller W, Cormier Y, Bernareggi A, Oldham F. Paclitaxel poliglumex (PPX) in combination with carboplatin (carb) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): preliminary data. J Clin Oncol 2005 ASCO Annu Meet Proc 2005;23:7230.
12. Dipetrillo T, Milas L, Evans D, et al. Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study. Am J Clin Oncol 2006;29:376-9.
13. Sabbatini P, Aghajanian C, Dizon D, et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol 2004;22:4523-31.
14. Veronese ML, Flaherty K, Kramer A, et al. Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2005;55:497-501.
15. Lin NU, Parker LM, Come SE, et al. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs 2007;25:369-75.
16. Gerth K, Bedorf N, Höfle G, Irschik H, Reichenbach H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996;49:560-3.
17. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-37.
18. Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003;21:1866-73.
19. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004;10:1289-98.
20. Shimizu T, Yamamoto N, Yamada Y, et al. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol 2008;61:751-8.
21. Whitehead RP, McCoy S, Rivkin SE, et al. A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 2006;24:515-20.
22. Vansteenkiste J, Lara PN, Jr., Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007;25:3448-55.
23. Hussain M, Tangen CM, Lara PN, Jr., et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005;23:8724-9.
24. Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and Taxol in human prostatic carcinoma cell lines. Cancer Res 1992;52:4433-40.
25. Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439-46.
26. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110:556-63.
27. Rosenberg JE, Galsky MD, Rohs NC, et al. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer 2006;106:58-62.
28. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726-34.
29. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415-20.
30. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25:3421-7.
31. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14.
32. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-406.
33. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7.
34. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-25.
35. Abrey L, Wen P, Govindan R, et al. Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II study. J Clin Oncol 2007 ASCO Annu Meet Proc 2007;25:18058.
36. Lin B, Catley L, LeBlanc R, et al. Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood 2005;105:350-7.
37. Mok TS, Choi E, Yau D, et al. Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. Oncology 2006;71:292-6.
38. O'Reilly T, Wartmann M, Maira SM, et al. Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemother Pharmacol 2005;55:307-17.
39. Sessa C, Perotti A, Lladò A, et al. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol 2007;18:1548-53.
40. Wartmann M, Loretan J, Reuter R, et al. Preclinical pharmacological profile of ABJ879, a novel epothilone B analog with potent and protracted anti-tumor activity. Proc Am Assoc Cancer Res 2004;45:abstract 5440.
41. Klar U, Buchmann B, Schwede W, et al. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 2006;45:7942-8.
42. Rustin G, Reed N, Jayson G, et al. Phase II trial of the novel epothilone ZK-EPO in patients with platinum resistant ovarian cancer. J Clin Oncol 2007 ASCO Annu Meet Proc 2007;25:5527.
43. Beer TM, Higano CS, Saleh M, et al. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 2007;25:565-70.
44. Monk J, Calero-Villalona M, Dupont J, et al. Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors. J Clin Oncol 2005 ASCO Annu Meet Proc 2005;23:2049.
45. Cortes J, Climent M, Gomez P, et al. Phase I trial of weekly combination KOS-862 (epothilone D) and trastuzumab in HER-2 overexpressing malignancies. J Clin Oncol 2006 ASCO Annu Meet Proc 2006;24:2028.
46. Marshall J, Ramalingam S, Hwang J, et al. Phase 1 and pharmacokinetic (PK) study of weekly KOS-862 (epothilone D) combined with gemcitabine (GEM) in patients (pts) with advanced solid tumors. J Clin Oncol 2005 ASCO Annu Meet Proc 2005;23:2041.
47. Overmoyer B, Waintraub S, Kaufman P, et al. Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer. J Clin Oncol 2005 ASCO Annu Meet Proc 2005;23:778.
48. Stopeck A, Moulder S, Jones S, et al. Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules. J Clin Oncol 2007 ASCO Annu Meet Proc 2007;25:2571.
49. Mita A, Lockhart A, Chen T, et al. A phase I pharmacokinetic (PK) trial of XAA296A (discodermolide) administered every 3 wks to adult patients with advanced solid malignancies. J Clin Oncol 2004 ASCO Annu Meet Proc 2004;22:2025.
50. Madiraju C, Edler MC, Hamel E, et al. Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin. Biochemistry 2005;44:15053-63.
51. Liu J, Towle MJ, Cheng H, et al. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res 2007;27:1509-18.
52. Wilmes A, Bargh K, Kelly C, Northcote PT, Miller JH. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines. Mol Pharmacol 2007;4:269-80.
53. Hamel E, Day BW, Miller JH, et al. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol 2006;70:1555-64.
54. Buey RM, Calvo E, Barasoain I, et al. Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites. Nat Chem Biol 2007;3:117-25.
55. Hamel E, Sackett DL, Vourloumis D, Nicolaou KC. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochemistry 1999;38:5490-8.
56. Kamath K, Okouneva T, Larson G, Panda D, Wilson L, Jordan MA. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol Cancer Ther 2006;5:2225-33.
57. Yee KW, Hagey A, Verstovsek S, et al. Phase 1study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2005;11:6615-24.
58. Nicholson B, Lloyd GK, Miller BR, et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 2006;17:25-31.
59. Bennouna J, Breton JL, Tourani JM, et al. Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer 2006;94:1383-8.
60. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95.
61. D'Agostino G, del Campo J, Mellado B, et al. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. Int JGynecol Cancer 2006;16:71-6.
62. Riely GJ, Gadgeel S, Rothman I, et al. A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer 2007;55:181-5.
63. McDermott D, Hersh E, Weber J, et al. ILX651 administered daily for five days every 3 weeks (qdx5dq3w) in patients (pts) with inoperable locally advanced or metastatic melanoma: phase II experience. J Clin Oncol 2005 ASCO Annu Meet Proc 2005;23:7556.